Dave Stadolnik

Dave Stadolnik currently serves as the API Major Capital Programs Director at Eli Lilly and Company, a position held since April 2025. Prior to this role, Stadolnik was the Owner's Representative at 5280 Project Management Consulting LLC, overseeing projects for Raytheon - Blue Canyon Technologies and AGC Biologics, as well as managing major capital programs for a confidential client, significantly contributing to their growth. Previous experience includes various leadership roles at Amgen between July 2006 and October 2010, where Stadolnik directed engineering management, plant readiness, operations management, quality management, partnerships, and technical services, demonstrating expertise in capital program oversight, risk management, and production operations.